SAI LIFE SCIENCES LIMITED (SAILIFE): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹1,836.8 latest close · +46.1% over the last 90 sessions

₹1,836.8 month-end · +107.7% over 12 months

₹1,836.8 month-end · +144.5% since Dec '24

52-week range ₹783.85 to ₹1897.30 · 1-year volatility 36.2%

Was the rally earned?

+108%share price, 1 yearLower P/E held it back

Mostly yes, with a catch.

Per-share earnings added 109 points, but investors now pay less per rupee of profit (P/E 108.4x to 107.3x), which took 1 point back.
The share count fell 29%.

Net profit growth+59 ptsNet profit rose about 49%, which lifts the price.

P/E change-1 ptsThe P/E fell from 108.4x to 107.3x, which lowers the price.

Share count change+50 ptsShare count fell 29%, which lifts the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-18.6%recovered 2026-02

1-year volatility36.2%annualised

Beta vs sector index1.203-year daily, correlation 0.47

Volume spikes5last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-18.6% (2026-01 peak to 2026-01 low, recovered 2026-02)

-17.9% (2025-01 peak to 2025-04 low, recovered 2025-07)

-17.1% (2026-09 peak to 2026-10 low, recovered 2026-11)

Most recent volume spikes

2026-11-09: 22.5x the 50-day median, price +5.3% that day

2026-11-06: 30.2x the 50-day median, price +12.0% that day

2026-09-02: 7.4x the 50-day median, price +4.5% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE71st▲ 25 pts vs a year ago
Op. margin83rd▲ 11 pts vs a year ago
Revenue growth66th
EPS growth89th
Debt/equity ↓65th▲ 10 pts vs a year ago
Cash cycle ↓99thflat vs a year ago
P/E ↓8th▼ 3 pts vs a year ago
12M momentum92nd

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~52%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 313.4x, a holder earning 12%/yr needs earnings to grow about 51.8%/yr for 10 years, then trade at 15x.

Delivered17.8%/yrEPS, last 8 fiscal years · 3-yr avg to 3-yr avg

Gap+33.9 ptsimplied minus delivered

Rank35thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	53.8%	55.2%	56.6%
15x	50.4%	51.8%	53.1%
20x	46.2%	47.5%	48.8%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 51.8%/yr

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹1836.80
P/E: 107.3x
ROCE: 20.0%
Market Cap: ₹39015 cr
Revenue (TTM): ₹2249 cr
P/S: 17.3x
P/B: 15.7x
ROE: 14.6%
Operating Margin: 27.0%
Debt / Equity: 0.1x
Promoter Holding: 34.5%
12M Momentum: 107.7%

52-week range

₹783.85₹1897.30

95% of the way from its 52-week low to its high

Price risk

1Y volatility

36.2%

Beta vs sector

1-year daily

1.18

Balance sheet & cash

Interest cover

operating profit ÷ interest

14.8x

Cash from profit, 3Y

operating cash flow ÷ net profit

1.80x

Share count, 1Y

unchanged

Are profits backed by cash?

4 of 5checks within range1 near a threshold

Other income reliance7%Within range

Other income as a share of pre-tax profit (trailing twelve months): 7.3%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate25%Within range

Median quarterly effective tax rate over about 2.5 years: 25.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.80xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.80x (cash from operations ₹1,086 cr, net profit ₹602 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress15% of fixed assetsWithin range

Capital work-in-progress is 15% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, DIIs added 20.8 pts; FIIs added 7.9 pts; promoters trimmed 0.7 pts.
The number of shareholders fell from 1.8 lakh to 1.3 lakh (-31%) between Dec 2024 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '24Jun '26Change

Promoters35.2%34.5%-0.7 pts

FIIs11.7%19.6%+7.9 pts

DIIs11.9%32.7%+20.8 pts

Public and others41.1%13.1%-28.0 pts

Number of shareholders

1.3 lakhshareholders-31% since Dec '24

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−8.2%typical 12-month return vs the marketBelow the base rate

We found 50 past situations where a non-financial company looked like SAI LIFE SCIENCES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −24% to +4% vs the market, against 0% for all non-financial companies in the same months.
The analogs' median sat below that base rate (gap −7.9%, 80% range −16.2% to −4.8%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median

−8.2%

All companies' median

−0.3%

Beat the market

32% vs 50%

50 past situations · 50 companies · 30 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
COHANCE Health Technology	Feb 2025	98x	19%	+93%	−9%	−78%
ASTRAL Producer Manufacturing	Mar 2020	72x	23%	+1%	−24%	+28%
IPCALAB Health Technology	Mar 2020	40x	16%	+42%	−8%	−24%
PIIND Process Industries	Apr 2020	54x	25%	+52%	−1%	−1%
RELAXO Consumer Non-Durables	Jan 2020	104x	26%	+101%	0%	−6%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
BERGEPAINT Process Industries	Feb 2020	111x	27%	+86%	−4%	−12%
KPITTECH Technology Services	May 2023	106x	24%	+101%	0%	−5%
POLYMED Health Technology	Oct 2024	102x	24%	+105%	0%	−32%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: size, revenue growth and P/E. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SAI LIFE SCIENCES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

NAVIN FLUORINE INTERNATIONAL LNAVINFLUOR

Process Industries

68%similar

market capROCE

RADICO KHAITANRADICO

Consumer Non-Durables

67%similar

P/Emarket cap

ASTRA MICROWAVE PRODUCTSASTRAMICRO

Electronic Technology

65%similar

ROCEP/E

METROPOLIS HEALTHCAREMETROPOLIS

Health Services

64%similar

operating margindebt/equity

SONA BLW PRECISION FORGINGSSONACOMS

Producer Manufacturing

62%similar

market cappromoter holding

NEULAND LABORATORIESNEULANDLAB

Health Technology

76%similar

promoter holdingrevenue

LAURUS LABSLAURUSLABS

Health Technology

49%similar

P/Epromoter holding

GLAND PHARMAGLAND

Health Technology

48%similar

operating marginmarket cap

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

12 events since Apr '25

2026
NovPriceVolume reached 30.2x its 50-day median on 2026-11-06; price +12.0% that day.
SepPriceVolume reached 7.4x its 50-day median on 2026-09-02; price +4.5% that day.
JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
MayPriceVolume reached 12.6x its 50-day median on 2026-05-15; price -1.9% that day.
FebPriceVolume reached 17.6x its 50-day median on 2026-02-06; price +4.8% that day.
2025
DecPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
DecDebtDebt / equity halved over 12 months to 0.17x.
DecSharesShare count is up 16.7% over 12 months.

Show 4 earlier events

2025
SepInstitutionsFII + DII holding rose 12.5 pts over 2 quarters to 36.2%.
SepPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
AugPriceVolume reached 115.8x its 50-day median on 2025-08-26; price -5.1% that day.
AprPriceVolume reached 22.4x its 50-day median on 2025-04-15; price +15.2% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history24 months · 2024-12 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	107.3x	₹2249 cr	14.6%	20.0%	0.1x
2026-10	91.0x	₹2249 cr	14.5%	20.0%	0.1x
2026-09	89.0x	₹2249 cr	14.5%	20.0%	0.1x
2026-08	88.1x	₹2191 cr	14.0%	20.0%	0.1x
2026-07	79.4x	₹2191 cr	14.0%	20.0%	0.1x
2026-06	74.5x	₹2191 cr	14.0%	20.0%	0.1x
2026-05	73.0x	₹2169 cr	15.6%	14.0%	0.2x
2026-04	67.3x	₹2169 cr	15.6%	14.0%	0.2x
2026-03	61.2x	₹2169 cr	15.6%	14.0%	0.2x
2026-02	72.7x	₹2053 cr	13.4%	14.0%	0.2x
2026-01	60.8x	₹2053 cr	13.4%	14.0%	0.2x
2025-12	66.2x	₹2053 cr	13.4%	14.0%	0.2x
2025-11	108.4x	₹1912 cr	11.5%	14.0%	0.2x
2025-10	112.5x	₹1912 cr	11.5%	14.0%	0.2x
2025-09	105.5x	₹1912 cr	11.5%	14.0%	0.2x
2025-08	101.1x	₹1696 cr	8.0%	14.0%	0.2x
2025-07	99.1x	₹1696 cr	8.0%	14.0%	0.2x
2025-06	94.8x	₹1696 cr	8.0%	14.0%	0.2x
2025-05	—	₹1555 cr	14.2%	11.0%	1.0x
2025-04	—	₹1555 cr	14.2%	11.0%	1.0x
2025-03	—	₹1555 cr	14.2%	11.0%	1.0x
2025-02	—	₹1499 cr	12.7%	11.0%	1.0x
2025-01	—	₹1499 cr	12.7%	11.0%	1.0x
2024-12	—	₹1499 cr	12.7%	11.0%	1.0x

Methodology and data notes